Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tirapazamine + KN046
- Development stage
- Unknown
- Lead developer
- AlphaMab Oncology
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intra-arterial, Intravenous
01
Overview
Tirapazamine + KN046 is a combination therapy comprising the bioreductive small molecule tirapazamine and the bispecific antibody KN046. Tirapazamine (SR-4233) is a hypoxia-activated cytotoxin that selectively targets hypoxic tumor cells by inducing DNA strand breaks and inhibiting topoisomerase II under low-oxygen conditions. KN046 is a recombinant humanized bispecific antibody targeting both Programmed Death-Ligand 1 (PD-L1) and Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4). This combination is primarily investigated for the treatment of liver metastases from colorectal cancer, utilizing transarterial tirapazamine injection followed by embolization (TATE) to create a hypoxic environment that activates tirapazamine while KN046 provides dual immune checkpoint blockade.
- Other names
- TATE + KN046tirapazamine plus KN046
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on tirapazamine + KN046.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tirapazamine + KN046.